This handout is for iatrogenic post-pvi atypical la flutter (gap-related macroreentry). Your care team identified this based on: atrial arrhythmia recurrence 1-12 months after pvi for af — post-blanking-period (hrs 2017 pmid 28506916) early recurrence window.
Other reasons your team may use this plan: ecg atypical flutter morphology (positive ii/iii/avf, prominent v1, mitral-isthmus or roof-circuit pattern) in patient with prior pvi; palpitations / dyspnea / fatigue / reduced exercise tolerance after recent (1-12 mo) pvi for af; organised atrial tachycardia (regular ventricular response with discrete p/f waves) on post-pvi holter or wearable.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| metoprolol_tartrate | 5 mg IV q5min × 3 then 25-50 mg PO BID | IV/PO | IV q5min × 3 → PO BID | AVN slowing for post-PVI flutter — ACC/AHA 2024 (PMID 38753446) |
| metoprolol_succinate | 25-50 mg PO daily; titrate | PO | daily | Long-acting BB bridge to redo ablation — ACC/AHA 2024 |
| amiodarone | 150 mg IV over 10 min then 1 mg/min × 6 h then 0.5 mg/min × 18 h; 200 mg PO daily maintenance | IV/PO | load + daily | Most efficacious AAD bridge to redo ablation; preferred over class IC (CAST PMID 1900101) given post-PVI scar substrate; pulm/thyroid/hepatic toxicity monitoring — ACC/AHA 2024 (PMID 38753446) |
| dofetilide | 125-500 mcg PO BID per CrCl (REMS — inpatient initiation) | PO | BID | Alternative to amiodarone; dofetilide REMS — must be initiated inpatient with QTc + CrCl monitoring — ACC/AHA 2024 (PMID 38753446) |
| apixaban | 5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) | PO | BID | AC same as AF; lifelong AC typical post-PVI given high mixed AF/AFL coexistence — ACC/AHA 2024 Class I (PMID 38753446); ARISTOTLE (PMID 21870978) |
| rivaroxaban | 20 mg with food (15 mg if CrCl 15-50) | PO | once daily | X-VeRT (PMID 24837375); VENTURE-AF (PMID 25975659) supports uninterrupted rivaroxaban during ablation |
| dabigatran | 150 mg BID (110 mg BID if age ≥75 or CrCl 30-50 in EU labelling) | PO | BID | RE-CIRCUIT (PMID 28530171) — uninterrupted dabigatran non-inferior to interrupted during AF ablation |
| warfarin | INR 2-3 | PO | daily | Mechanical valve / severe MS — only warfarin — ACC/AHA 2024 |
Plan: Iatrogenic post-PVI atypical LA flutter — rate control + AAD bridge + AC + REDO 3D electroanatomic mapping ablation pathway with gap targeting + linear lesion completion — ACC/AHA 2024 (Joglar PMID 38753446); HRS 2017 (Calkins PMID 28506916)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
EP clinic at 4 weeks post-redo with 12-lead + Holter; AC continuation lifelong (mixed AF/AFL); lifestyle (alcohol, weight, OSA per LEGACY); 3, 6, 12-month Holter or wearable; counsel re: atrioesophageal fistula warning weeks 2-6 post-LA ablation
Guideline: 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar Circulation 2024 PMID 38753446); HRS/EHRA/ECAS/APHRS/SOLAECE 2017 expert consensus on AF catheter and surgical ablation (Calkins HeartRhythm 2017 PMID 28506916); ESC 2024 AF (Van Gelder PMID 39050851)